Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center62
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York96
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT04881240RecruitingPhase 1
Donor T-cell therapy for CD19-positive leukemia in young patients
This study tests a new treatment using donor immune cells (T-cells) that target a protein called CD19 on leukemia cells. It is for children and young adults with CD19-positive leukemia that has come back or not responded to standard treatments.
Memphis, TennesseeAges Up to 21 years - NCT04861064RecruitingPhase 2
Weekly sirolimus for blood and lymph vessel malformations
This trial studies whether taking sirolimus once a week can improve blood vessel, lymph vessel, or mixed (venolymphatic) malformations. It may help reduce symptoms and lesion size, while also monitoring safety in children and adults.
Charleston, South CarolinaAges 2 years+ - NCT04888338Recruiting
Studying outcomes after CAR-T, radiation, or bispecific therapy
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
Houston, TexasAges 18 years+ - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT04858256RecruitingPhase 2
Pacritinib for relapsed or resistant T-cell blood cancers
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT04855695RecruitingPhase 1/Phase 2
Study for relapsed mantle cell lymphoma using targeted oral drugs
This Phase 1/2 study tests a combination of oral and antibody treatments for mantle cell lymphoma that has come back (relapsed) or did not respond (refractory). It aims to control the cancer and uses blood/tumor test results to guide some treatment timing for eligible participants.
Chicago, IllinoisAges 18 years+ - NCT03481881Recruiting
Drug dosing study in children getting routine medicines
This study measures how children’s bodies handle medicines they are already prescribed as standard care. It may help doctors choose safer, more accurate doses for children in the future.
Durham, North CarolinaAges birth–20 years - NCT03849443RecruitingEarly Phase 1
Testing tranexamic acid to reduce bleeding after spine fusion
This trial studies whether a single dose or multiple doses of tranexamic acid (TXA) can reduce the chance you need a blood transfusion after spine fusion surgery. It also compares two different ways TXA may be given (by mouth and through a vein) to see which approach works best and is safe.
Chicago, IllinoisAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT04815356RecruitingPhase 1
T cells designed to attack a blood cancer called hairy cell leukemia
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
Bethesda, MarylandAges 18 years+ - NCT04840602RecruitingPhase 2
Venetoclax plus rituximab versus standard Waldenstrom treatment
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Tucson, ArizonaAges 18 years+ - NCT03329274Recruiting
Histiocytosis patient registry for Erdheim-Chester and related diseases
This is a registry (a research database) for people with Erdheim-Chester disease and other related “histiocytosis” conditions. It collects past and future medical information to better understand these illnesses and support future research.
New York, New YorkAges 18 years+ - NCT04448184RecruitingPhase 3
Platelet transfusion strategy during stem cell transplant
This trial compares how platelets are given during a stem cell transplant to help prevent bleeding. It also watches for clotting risks, since platelets can affect both bleeding and clot formation.
Calgary, AlbertaAges 18 years+ - NCT04640987RecruitingPhase 1
Stem cell transplant with added T-cells for blood cancers
This Phase 1 study tests a stem cell transplant plan that uses donor T-cells that have been specially processed and then added back. It aims to see if this approach is safer and works better for children and adults with serious blood cancers who need a transplant.
Palo Alto, CaliforniaAges 1 month–45 years - NCT04644211RecruitingPhase 2
Ruxolitinib for symptom control in certain blood cancer types
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
Boston, MassachusettsAges 18 years+ - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT04804891RecruitingPhase 1
Personalized immune medicine plan after intestinal transplant
This Phase 1 study tests a way to lower (minimize) the immune-suppressing medicines after an intestinal transplant while still keeping the new organ safe. It uses blood tests that look at immune activity and “chimerism” to guide how strong the immune suppression needs to be.
New York, New YorkAges 18–65 - NCT04794296Recruiting
Care plan for children newly diagnosed with acute lymphoblastic leukemia
This trial uses a standard treatment plan for children who have just been diagnosed with acute lymphoblastic leukemia (ALL). It aims to guide the best initial treatment for certain cell types of ALL and help improve outcomes while avoiding specific higher-risk subtypes.
AbidjanAges Up to 18 years - NCT04806620Recruiting
Online app study for brain inflammation lifestyle data
This study uses a digital platform (app/website) to collect lifestyle and symptom information to better understand brain inflammation. You may qualify if you have certain conditions like Long COVID, migraines, autoimmune disease, inflammatory gut issues, mood disorders, or if you are a healthy comparison person.
Delafield, WisconsinAges 2 years+ - NCT04776941Recruiting
Writing exercises to reduce stress after cancer
This study tests whether guided writing exercises can help cancer survivors manage stress. It may be a low-risk way to improve well-being after cancer, especially if you recently finished treatment.
Houston, TexasAges 18 years+ - NCT04792502RecruitingPhase 2
Mosunetuzumab plus lenalidomide for untreated follicular or marginal lymphoma
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
New Haven, ConnecticutAges 18 years+ - NCT04774393RecruitingPhase 1/Phase 2
Study for AML after it returns or resists treatment
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
Houston, TexasAges 18 years+ - NCT04836390Enrolling by invitationPhase 2
Donor immune cell treatment after transplant for high-risk AML
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Phoenix, ArizonaAges birth–25 years - NCT04848064RecruitingPhase 1
Natural killer cells plus mogamulizumab for skin lymphoma
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
Columbus, OhioAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,407 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.